• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Aspire Biopharma Holdings Inc.

    2/12/26 1:00:30 PM ET
    $ASBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASBP alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Aspire Biopharma Holdings, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    738920107

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    738920107


    1Names of Reporting Persons

    Ardsley Advisory Partners LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,750,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,750,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,750,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.76 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP No.
    738920107


    1Names of Reporting Persons

    Ardsley Advisory Partners GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,750,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,750,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,750,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.76 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    738920107


    1Names of Reporting Persons

    Ardsley Partners I GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,750,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,750,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,750,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.76 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    738920107


    1Names of Reporting Persons

    Ardsley Partners Advanced Healthcare Fund, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    9,229,100.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    9,229,100.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,229,100.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.67 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    738920107


    1Names of Reporting Persons

    Ardsley Partners Fund II, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,520,900.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,520,900.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,520,900.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.10 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    738920107


    1Names of Reporting Persons

    Philip J. Hempleman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,750,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,750,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,750,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.76 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Aspire Biopharma Holdings, Inc.
    (b)Address of issuer's principal executive offices:

    23150 Fashion Drive, Suite 232, Estero, Florida 33928
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G (the "Schedule") is being filed with respect to shares of Common Stock (as defined below) of Aspire Biopharma Holdings, Inc. (the "Issuer") which are beneficially owned by Ardsley Advisory Partners LP (the "Advisor"), Ardsley Advisory Partners GP LLC (the "Advisor General Partner"), Ardsley Partners I GP LLC (the "General Partner"), Ardsley Partners Advanced Healthcare Fund, L.P. (the "Advanced Healthcare Fund"), Ardsley Partners Fund II, L.P. ("Fund II") and Phillip J. Hempleman ("Hempleman", and together with the Advisor, the Advisor General Partner, the General Partner, the Advanced Healthcare Fund and Fund II, collectively, the "Reporting Persons"). See Item 4 below.
    (b)Address or principal business office or, if none, residence:

    105 Rowayton Ave. Norwalk, CT 06853
    (c)Citizenship:

    Each of the Advisor, the Advanced Healthcare Fund and Fund II is a Delaware limited partnership. Each of the Advisor General Partner and the General Partner is a Delaware limited liability company. Hempleman is a United States Citizen.
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    738920107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Ardsley Advisory Partners LP - 10,750,000 Ardsley Advisory Partners GP LLC - 10,750,000 Ardsley Partners I GP LLC - 10,750,000 Ardsley Partners Advanced Healthcare Fund, L.P. - 9,229,100 Ardsley Partners Fund II, L.P. - 1,520,900 Philip J. Hempleman - 10,750,000
    (b)Percent of class:

    Ardsley Advisory Partners LP - 7.76 Ardsley Advisory Partners GP LLC - 7.76 Ardsley Partners I GP LLC - 7.76 Ardsley Partners Advanced Healthcare Fund, L.P. - 6.67 Ardsley Partners Fund II, L.P. - 1.10 Philip J. Hempleman - 7.76
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Ardsley Advisory Partners LP - 0 Ardsley Advisory Partners GP LLC - 0 Ardsley Partners I GP LLC - 0 Ardsley Partners Advanced Healthcare Fund, L.P. - 0 Ardsley Partners Fund II, L.P. - 0 Philip J. Hempleman - 0

     (ii) Shared power to vote or to direct the vote:

    Ardsley Advisory Partners LP - 10,750,000 Ardsley Advisory Partners GP LLC - 10,750,000 Ardsley Partners I GP LLC - 10,750,000 Ardsley Partners Advanced Healthcare Fund, L.P. - 9,229,100 Ardsley Partners Fund II, L.P. - 1,520,900 Philip J. Hempleman - 10,750,000

     (iii) Sole power to dispose or to direct the disposition of:

    Ardsley Advisory Partners LP - 0 Ardsley Advisory Partners GP LLC - 0 Ardsley Partners I GP LLC - 0 Ardsley Partners Advanced Healthcare Fund, L.P. - 0 Ardsley Partners Fund II, L.P. - 0 Philip J. Hempleman - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Ardsley Advisory Partners LP - 10,750,000 Ardsley Advisory Partners GP LLC - 10,750,000 Ardsley Partners I GP LLC - 10,750,000 Ardsley Partners Advanced Healthcare Fund, L.P. - 9,229,100 Ardsley Partners Fund II, L.P. - 1,520,900 Philip J. Hempleman - 10,750,000

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit 2.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Ardsley Advisory Partners LP
     
    Signature:/s/ Steve Napoli
    Name/Title:Steve Napoli/ Member
    Date:02/12/2026
     
    Ardsley Advisory Partners GP LLC
     
    Signature:/s/ Steve Napoli
    Name/Title:Steve Napoli/ Member
    Date:02/12/2026
     
    Ardsley Partners I GP LLC
     
    Signature:/s/ Steve Napoli
    Name/Title:Steve Napoli/ Member
    Date:02/12/2026
     
    Ardsley Partners Advanced Healthcare Fund, L.P.
     
    Signature:/s/ Steve Napoli
    Name/Title:Steve Napoli/ Member
    Date:02/12/2026
     
    Ardsley Partners Fund II, L.P.
     
    Signature:/s/ Steve Napoli
    Name/Title:Steve Napoli/ Member
    Date:02/12/2026
     
    Philip J. Hempleman
     
    Signature:/s/ Steve Napoli*
    Name/Title:Steve Napoli/Attorney-in Fact for Philip J. Hempleman
    Date:02/12/2026

    Comments accompanying signature:  * Executed by Steve Napoli as Attorney-in-Fact for Philip J. Hempleman. The Power of Attorney for Mr. Hempleman is attached as Exhibit 2 to the Statement on Schedule 13G with respect to the Common Stock of Vaxgen, Inc., filed on February 15, 2006, and is incorporated herein by reference.
    Get the next $ASBP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASBP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ASBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Fell Donald G. bought $7,800 worth of shares (20,000 units at $0.39) (SEC Form 4)

    4/A - Aspire Biopharma Holdings, Inc. (0001847345) (Issuer)

    6/10/25 5:25:23 PM ET
    $ASBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fell Donald G. increased direct ownership by 5% to 20,000 units (SEC Form 4)

    4 - Aspire Biopharma Holdings, Inc. (0001847345) (Issuer)

    6/6/25 5:00:59 PM ET
    $ASBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASBP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Fell Donald G. bought $7,800 worth of shares (20,000 units at $0.39) (SEC Form 4)

    4/A - Aspire Biopharma Holdings, Inc. (0001847345) (Issuer)

    6/10/25 5:25:23 PM ET
    $ASBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fell Donald G. increased direct ownership by 5% to 20,000 units (SEC Form 4)

    4 - Aspire Biopharma Holdings, Inc. (0001847345) (Issuer)

    6/6/25 5:00:59 PM ET
    $ASBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASBP
    SEC Filings

    View All

    SEC Form S-1 filed by Aspire Biopharma Holdings Inc.

    S-1 - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)

    2/17/26 4:16:30 PM ET
    $ASBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Aspire Biopharma Holdings Inc.

    PRE 14A - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)

    2/12/26 5:29:03 PM ET
    $ASBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Aspire Biopharma Holdings Inc.

    SCHEDULE 13G - Aspire Biopharma Holdings, Inc. (0001847345) (Subject)

    2/12/26 1:00:30 PM ET
    $ASBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASBP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

    MIAMI, April 16, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - TodayApril 16, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to t

    4/16/25 7:00:00 AM ET
    $ASBP
    $BENF
    $BNZI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance: Consumer Services
    Finance

    Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream

    MIAMI, April 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 81th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1April 16, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already register

    4/15/25 7:00:00 AM ET
    $ASBP
    $BENF
    $BNZI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance: Consumer Services
    Finance